Novocure Company Insiders
NVCR Stock | USD 19.59 0.10 0.51% |
Novocure's insiders are aggressively selling. The analysis of insiders' sentiment of trading Novocure stock suggests that virtually all insiders are panicking at this time. Novocure employs about 1.5 K people. The company is managed by 18 executives with a total tenure of roughly 42 years, averaging almost 2.0 years of service per executive, having 82.67 employees per reported executive.
Asaf Danziger CEO CEO and Director |
William Doyle Chairman Executive Chairman |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2024-11-01 | Mukund Paravasthu | Disposed 160 @ 15.88 | View | ||
2024-10-31 | Michal Nath Puri | Disposed 810 @ 15.79 | View | ||
2024-08-02 | Ashley Cordova | Disposed 688 @ 20.14 | View | ||
2024-06-04 | W Anthony Vernon | Disposed 964 @ 23.89 | View |
Monitoring Novocure's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Novocure |
Novocure's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Novocure's future performance. Based on our forecasts, it is anticipated that Novocure will maintain a workforce of slightly above 1490 employees by April 2025.Novocure Management Team Effectiveness
The company has return on total asset (ROA) of (0.0877) % which means that it has lost $0.0877 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4667) %, meaning that it created substantial loss on money invested by shareholders. Novocure's management efficiency ratios could be used to measure how well Novocure manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/18/2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to drop to -0.37. At this time, Novocure's Non Current Assets Total are relatively stable compared to the past year. As of 03/18/2025, Non Currrent Assets Other is likely to grow to about 15.3 M, while Net Tangible Assets are likely to drop slightly above 267.8 M.As of 03/18/2025, Common Stock Shares Outstanding is likely to drop to about 98 M. In addition to that, Net Loss is likely to drop to about (111.7 M)
Novocure Workforce Comparison
Novocure is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 44,737. Novocure holds roughly 1,488 in number of employees claiming about 3% of equities under Health Care industry.
Novocure Profit Margins
The company has Profit Margin (PM) of (0.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.39.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.5 | 0.7733 |
|
|
Novocure Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Novocure insiders, such as employees or executives, is commonly permitted as long as it does not rely on Novocure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Novocure insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.85 | 17 | 20 | 1,730,622 | 44,817 |
2024-12-01 | 0.8333 | 5 | 6 | 77,212 | 14,052 |
2024-06-01 | 4.6 | 23 | 5 | 214,611 | 134,958 |
2024-03-01 | 0.6667 | 16 | 24 | 1,489,515 | 179,501 |
2023-12-01 | 1.6 | 8 | 5 | 113,296 | 18,350 |
2023-03-01 | 0.7292 | 35 | 48 | 734,199 | 523,934 |
2022-12-01 | 1.0 | 3 | 3 | 20,439 | 15,508 |
2022-09-01 | 0.6111 | 11 | 18 | 14,868 | 52,862 |
2022-06-01 | 0.6 | 12 | 20 | 75,778 | 41,208 |
2022-03-01 | 1.0417 | 25 | 24 | 325,126 | 64,060 |
2021-12-01 | 3.0 | 3 | 1 | 4,974 | 209.00 |
2021-09-01 | 0.3878 | 19 | 49 | 44,261 | 189,462 |
2021-06-01 | 0.449 | 22 | 49 | 37,681 | 276,842 |
2021-03-01 | 0.4839 | 30 | 62 | 311,025 | 225,346 |
2020-12-01 | 0.1818 | 6 | 33 | 136,907 | 452,153 |
2020-09-01 | 0.3094 | 43 | 139 | 353,770 | 952,382 |
2020-06-01 | 0.6875 | 22 | 32 | 406,132 | 644,730 |
2020-03-01 | 0.9444 | 34 | 36 | 1,158,839 | 994,692 |
2019-12-01 | 0.3425 | 25 | 73 | 380,407 | 1,962,118 |
2019-09-01 | 0.3176 | 27 | 85 | 346,771 | 953,298 |
2019-06-01 | 0.76 | 57 | 75 | 1,767,677 | 2,181,883 |
2019-03-01 | 0.6032 | 76 | 126 | 2,143,248 | 3,266,745 |
2018-12-01 | 0.6667 | 4 | 6 | 48,781 | 81,412 |
2018-09-01 | 0.2241 | 13 | 58 | 191,500 | 1,305,170 |
2018-06-01 | 0.5068 | 37 | 73 | 1,999,659 | 2,047,679 |
2018-03-01 | 1.3182 | 29 | 22 | 1,622,166 | 642,328 |
2017-09-01 | 0.3333 | 6 | 18 | 367,195 | 1,081,938 |
2017-06-01 | 0.1429 | 8 | 56 | 1,887,536 | 1,803,696 |
2017-03-01 | 1.2667 | 19 | 15 | 9,650,031 | 23,718,725 |
2016-12-01 | 0.0667 | 1 | 15 | 156,073 | 338,573 |
2016-09-01 | 0.1111 | 1 | 9 | 676,576 | 1,353,152 |
2016-06-01 | 1.2727 | 14 | 11 | 1,678,771 | 1,804,779 |
2016-03-01 | 8.0 | 8 | 1 | 1,137,984 | 332,984 |
2015-12-01 | 0.1867 | 14 | 75 | 37,400,959 | 46,737,117 |
Novocure Notable Stakeholders
A Novocure stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novocure often face trade-offs trying to please all of them. Novocure's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novocure's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Asaf Danziger | CEO and Director | Profile | |
William Doyle | Executive Chairman | Profile | |
Piet MD | Head VP | Profile | |
Barak BenArye | General Counsel | Profile | |
William Burke | Chief Officer | Profile | |
Frank Leonard | Executive Oncology | Profile | |
Christoph Brackmann | Chief Officer | Profile | |
Uri MD | Chief Officer | Profile | |
Pritesh Shah | Chief Commercial Officer | Profile | |
Ashley Cordova | Chief Officer | Profile | |
Moshe Giladi | Chief Officer | Profile | |
Wilhelmus Groenhuysen | Chief Officer | Profile | |
Pr MD | Founder CTO | Profile | |
MBA MD | Chief Officer | Profile | |
Ingrid Goldberg | VP Relations | Profile | |
Barak Arye | General Counsel | Profile | |
Mukund Paravasthu | Chief Officer | Profile | |
Michael Puri | Chief Officer | Profile |
About Novocure Management Performance
The success or failure of an entity such as Novocure often depends on how effective the management is. Novocure management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novocure management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novocure management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.14) | (0.14) | |
Return On Capital Employed | (0.35) | (0.37) | |
Return On Assets | (0.14) | (0.14) | |
Return On Equity | (0.47) | (0.49) |
Novocure Workforce Analysis
Traditionally, organizations such as Novocure use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novocure within its industry.Novocure Manpower Efficiency
Return on Novocure Manpower
Revenue Per Employee | 406.7K | |
Revenue Per Executive | 33.6M | |
Net Loss Per Employee | 113.3K | |
Net Loss Per Executive | 9.4M | |
Working Capital Per Employee | 235.3K | |
Working Capital Per Executive | 19.5M |
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.